Drug-related deaths in the United Kingdom

Scotland's legal go-ahead for safer drug consumption rooms is a gamechanger

Retrieved on: 
Saturday, September 16, 2023
Misuse of Drugs Act 1971, Lord, HIV, Solution, NHS Greater Glasgow and Clyde, Policy, Health and Social Care Partnership, Research, Aircraft, History, Lord Advocate, Government, Abuse, Drug, Environment, News, Drug-related deaths in the United Kingdom, GameChanger, Pharmaceutical industry, Interior design, Medical device

Dorothy Bain KC, Lord Advocate of Scotland Scotland’s most senior law officer, the Lord Advocate, has released a statement that would enable NHS Glasgow and Clyde to open a safer drug consumption facility (SDCF) in the city.

Key Points: 
  • Dorothy Bain KC, Lord Advocate of Scotland Scotland’s most senior law officer, the Lord Advocate, has released a statement that would enable NHS Glasgow and Clyde to open a safer drug consumption facility (SDCF) in the city.
  • Also known as overdose prevention centres, SDCFs are spaces where people can take their own drugs under supervision.
  • They also provide non-judgmental settings where people who use drugs can access wider support or be directed to other services.
  • Safer consumption rooms are viewed by many as a critical element of this broader response.

Changing approaches to drug harms

    • The request was declined on the basis that what it sought was too broad and beyond the remit of the Lord Advocate.
    • Last year a new, narrower request was put to the current Lord Advocate, Dorothy Bain.
    • The Scottish secretary Alister Jack has since confirmed that “the UK government will not intervene” to prevent a safer consumption room being established.

An essential first step

    • It is of enormous significance and will be welcomed by many across the UK who believe these centres can play a vital role in tackling drug harms.
    • The terms of the Lord Advocate’s statement are, however, strictly constrained.
    • It applies specifically to the Glasgow pilot and is based on assessment of its particular design, setting and operating procedures.
    • If we are to really understand the role safer consumption rooms can play in tackling drug harms, we need multiple pilots and evaluations.

An Innovative Solution to Tackling the Escalating US Drug Crisis

Retrieved on: 
Thursday, August 31, 2023
Therapeutic drug monitoring, Face, Public, Support, Multimedia, Privacy, Doctor of Philosophy, PULSE, Drug-related deaths in the United Kingdom, Synthetic, Medical device, Vaccine, Management, Online shopping

CARLSBAD, Calif., Aug. 31, 2023 /PRNewswire-PRWeb/ -- In the wake of an escalating drug crisis, a consortium of experts, including Corina J Shtir, PhD., Rockwell Herron, Christopher Nielsen, Paul Scott, Jonathan Martin, and John Shtir, releases a groundbreaking whitepaper titled "Facing the Drug Pandemic Problem in the United States: An Epidemiological Approach to Assess Drug Use and Support Preventive Measures." This comprehensive study exposes the alarming rise in drug-related deaths and introduces a cutting-edge technological approach to counter the crisis.

Key Points: 
  • A consortium of experts is addressing the escalating US drug crisis, unveiling a technological approach to counter it.
  • This comprehensive study exposes the alarming rise in drug-related deaths and introduces a cutting-edge technological approach to counter the crisis.
  • "In the face of a growing and complex drug crisis, we need a dynamic and data-driven approach that can adapt rapidly."
  • The whitepaper addresses the gravity of the drug crisis and introduces the PULSE platform as a potent weapon against drug poisoning.

Northeast Delta HSA unveils Harm-Reduction Vending Machines; effort to reduce drug overdose, misuse

Retrieved on: 
Friday, August 11, 2023
Harm reduction, Education, HIV, Pregnancy test, Senior counsel, Public, Drug-related deaths in the United Kingdom, Risk, LA, Health, Substance abuse, Mobile phone, Dietary supplement

MONROE, La., Aug. 11, 2023 /PRNewswire-PRWeb/ -- Northeast Delta Human Services Authority (NEDHSA) announces the launch of its innovative harm-reduction vending machines. These state-of-the-art machines are designed to provide critical resources and support to individuals at risk of substance abuse, promoting harm reduction and improving public health outcomes.

Key Points: 
  • Northeast Delta Human Services Authority (NEDHSA) announces the launch of its innovative harm-reduction vending machines.
  • MONROE, La., Aug. 11, 2023 /PRNewswire-PRWeb/ -- Northeast Delta Human Services Authority (NEDHSA) announces the launch of its innovative harm-reduction vending machines.
  • The first vending machine placement will be in the Phoenix Peer Support Center at 722 Adams Street, Monroe, LA 71201.
  • For more information regarding the Harm Reduction Vending Machine and other harm reduction topics, contact Kara Etienne at [email protected] .

Opioids and cocaine are a deadly combination – and 'polydrug' deaths are rising

Retrieved on: 
Monday, July 31, 2023
Blood pressure, Drug-related deaths in the United Kingdom, Dopamine, Consciousness, Drug overdose, Methamphetamine, Palpitations, Heroin, Stroke, Hyperthermia, European Monitoring Centre for Drugs and Drug Addiction, The Rev, Fentanyl, Brain, CDC, Amphetamine, Death, Man, Methylphenidate, Protein, Morphine, Cocaine, Hypoventilation, Risk, Euphoria, Korea Disease Control and Prevention Agency, Methadone, Center, Respiratory failure, Pharmaceutical industry, Drug, Cereal

Drug-related deaths associated with stimulants, such as cocaine, methamphetamine, amphetamine and methylphenidate, doubled between 2011 and 2021.

Key Points: 
  • Drug-related deaths associated with stimulants, such as cocaine, methamphetamine, amphetamine and methylphenidate, doubled between 2011 and 2021.
  • And deaths associated with using both stimulants and opioids, such as heroin, morphine, fentanyl and methadone, increased by about sevenfold over the same period.
  • Cocaine and methamphetamine are stimulant drugs, whereas opioids, such as heroin and methadone, are depressants.
  • Taken together, it can be seen that there may be a worldwide increase in polydrug-related deaths and in particular those involving both stimulants and opioids.

How getting out into nature can help people with drug and alcohol problems

Retrieved on: 
Wednesday, May 10, 2023
Learning, Pressure, Awareness, Public, Garden, Policy, Research, Loneliness, Gardening, Death, Drug-related deaths in the United Kingdom, Nature, Time, Mental, Camping, Physical fitness, Health, Mental health, Nursing, Tourism, Medicinal plants, Pharmaceutical industry, Drug

They told us the reasons why these programmes are effective for people with drug and alcohol problems are similar to why they improve mental health.

Key Points: 
  • They told us the reasons why these programmes are effective for people with drug and alcohol problems are similar to why they improve mental health.
  • This is important given the high levels of loneliness and isolation reported by many people with alcohol and drug problems.
  • Finally, the development of relationships with other people on the programmes who haven’t faced drug and alcohol problems can reduce stigma.
  • We know stigma experienced by people with drug and alcohol problems can increase the likelihood of harm from substances and reduce inclination to get help.

High levels of drug-related deaths

    • In 2021, there were 4,859 drug-related deaths registered in England and Wales, and 1,330 in Scotland.
    • In the same year, 9,641 alcohol-related deaths were recorded in the UK.
    • For example, in deprived areas of Scotland, deaths from both drugs and alcohol are significantly higher.
    • Politicians, researchers and drug treatment experts have described the level of drug-related harm in the UK as a public health emergency.

Aptose Reports Results for the First Quarter 2023

Retrieved on: 
Monday, May 8, 2023
TP53, APS, CRH, NPM1, Aes, Food and Drug Administration, Clinical trial, G1, Absorption, Aplastic anemia, Trial of the century, Acute myeloid leukemia, Phase 1, AML, Running, Drug-related deaths in the United Kingdom, MLL, Patient, RAS, SAN, EHA, RUNX1, IDH, FLT3, TSX, CRi, Toxic leukoencephalopathy, Infrared spectroscopy correlation table, FDA, CRP, Gene, Safety, Pharmaceutical industry, DNMT3A, G3

─ Brisk Enrollment of Tuspetinib Monotherapy and Doublet Arms in APTIVATE Expansion Trial;

Key Points: 
  • ─ Brisk Enrollment of Tuspetinib Monotherapy and Doublet Arms in APTIVATE Expansion Trial;
    SAN DIEGO and TORONTO, May 08, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced financial results for first quarter ended March 31, 2023, and provided a corporate update.
  • “While it is still too early to report confirmed responses in the APTIVATE trial, it is moving in the right direction.
  • Aptose has identified a safe therapeutic range with a broad therapeutic window, spanning the dose levels of 40, 80, 120 and 160 milligrams.
  • If findings continue as anticipated, Aptose plans to escalate the dose of G3 and seek a dose with robust safety and higher exposure levels.

Masimo Opioid Halo™ Granted De Novo for the First and Only FDA-Authorized Opioid Overdose Prevention and Alert System

Retrieved on: 
Monday, April 3, 2023
Software, Mobile, Wireless, Pharmaceutical, Telemedicine, Virtual Medicine, Consumer Electronics, Consumer, Mental Health, Apps, Applications, Technology, Medical Devices, Other Consumer, FDA, Health, CHC, Intermountain Health, Tonsillectomy, De novo, Friends, Naloxone, LAUNCH (Innovation Challenge), RRT, Parent, COVID-19, Opioid use disorder, Opioid overdose, Prescription, Physiology, Multimedia, COVID, Heroin, Movement, Pain, EMS, Drug-related deaths in the United Kingdom, MASI, Patient, De novo gene birth, Risk, OTC, Research, Death, Fentanyl, Family, Caregiver, Cereal, Nursing, Masimo

Masimo (NASDAQ: MASI) today announced that Masimo Opioid Halo™ , an opioid overdose prevention and alert system, has been granted a De Novo by the FDA – making it the first and only FDA-cleared monitoring solution for detecting opioid-induced respiratory depression, the leading cause of death from opioid overdose.

Key Points: 
  • Masimo (NASDAQ: MASI) today announced that Masimo Opioid Halo™ , an opioid overdose prevention and alert system, has been granted a De Novo by the FDA – making it the first and only FDA-cleared monitoring solution for detecting opioid-induced respiratory depression, the leading cause of death from opioid overdose.
  • With the De Novo, Masimo also becomes the first winner of an FDA Opioid Innovation Challenge to have an authorized solution designed to help solve the U.S. opioid crisis.
  • Opioid Halo advances the forefront of continuous monitoring through its unique Opioid Halo engine, an advanced pattern recognition algorithm which helps detect and quantify the risk of severe opioid-induced respiratory depression.
  • And today, we are delighted to have received the first De Novo for our response to that Innovation Challenge, Masimo Opioid Halo.

The Partnership for a Drug-Free New Jersey Addresses Surging Substance Use-Related Deaths Among Older Adults

Retrieved on: 
Saturday, December 10, 2022
Communication, Fentanyl, Advertising, Death, Government, Illegal drug trade, Drug-related deaths in the United Kingdom, CDC, Partnership, Organization, Caregiver, Patient, Health insurance, Pharmaceutical industry

New Jersey, Dec. 10, 2022 (GLOBE NEWSWIRE) -- Drug-related deaths are on the rise among older adults in the United States, and the Partnership for a Drug-Free New Jersey (PDFNJ) is raising awareness about the dangers associated with prescription opioids among this vulnerable population.

Key Points: 
  • New Jersey, Dec. 10, 2022 (GLOBE NEWSWIRE) -- Drug-related deaths are on the rise among older adults in the United States, and the Partnership for a Drug-Free New Jersey (PDFNJ) is raising awareness about the dangers associated with prescription opioids among this vulnerable population.
  • Deaths from drug overdoses among seniors have more than tripled in the past two decades, according to the CDC .  Between 2000 and 2020, the rates rose from 2.4 to 8.8 deaths per 100,000 people among adults 65 and older.
  • The data also found that fentanyl and other synthetic opioids are affecting this population with death rates from these drugs increasing by 53 percent from 2019 to 2020.
  • “To combat the opioid epidemic and keep New Jersey residents safe, it is crucial that we raise awareness of the dangers of prescription opioids among older adults, their families and caregivers,” said Valente.

Mental Health America receives $3.5 million grant from Elevance Health Foundation for substance use, addiction disorders program

Retrieved on: 
Thursday, October 20, 2022
Online, Color, Substance abuse, Motivation, Clifford Whittingham Beers, Organization, Foundation, Research, Program, Drug-related deaths in the United Kingdom, BIPOC, Mental health, Addiction, Knowledge, Substance, MHA, CEO, Shame, GLOBE, Internet, COVID-19, Solution, Tobacco, Pharmaceutical industry

Alexandria, VA, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Mental Health America (MHA) today announced that it is a recipient of a $3.5 million grant from Elevance Health Foundation, the philanthropic arm of Elevance Health Inc., to expand its efforts in online interventions for substance use and addiction disorders.

Key Points: 
  • Alexandria, VA, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Mental Health America (MHA) today announced that it is a recipient of a $3.5 million grant from Elevance Health Foundation, the philanthropic arm of Elevance Health Inc., to expand its efforts in online interventions for substance use and addiction disorders.
  • Early intervention is critical to effectively treating all mental health conditions, including addiction.
  • Substance use disorders alone affect more than 20 million Americans ages 12 and over, and 9.5 million adults report having both a substance use disorder and a mental illness.
  • This grant is part of Elevance Health Foundations commitment of up to $30 million over the next three years to support programs that address mental health, with an emphasis on substance use disorder.

Inmar Intelligence Shines Light on National Need for Education and Access to Prescription Drug Disposal Services with its Upcoming Consumer Drug Take-Back Event

Retrieved on: 
Monday, October 17, 2022
LinkedIn, Health care, Solution, DEA, Drug, National, Twitter, Drug-related deaths in the United Kingdom, History, Awareness, Drug Enforcement Administration, Technology, Plasma protein binding, Marketing, Commerce, GLOBE, Child, Prescription, Pharmaceutical industry, Facebook

The drive-thru event will occur on October 29th in conjunction with the Drug Enforcement Administration (DEA), Winston-Salem Police Department and Forsyth County Sheriff's Department.

Key Points: 
  • The drive-thru event will occur on October 29th in conjunction with the Drug Enforcement Administration (DEA), Winston-Salem Police Department and Forsyth County Sheriff's Department.
  • Following the fantastic community response from our earlier drug take-back events, we are thrilled to host our fifth annual event in our home town of Winston-Salem, said Ann-Marie Daugherty, President of Supplytech at Inmar Intelligence.
  • In a 2022 Inmar Intelligence National Survey on Consumer Drug Take-Back Awareness, 64 percent of respondents have unused, leftover or expired medications in their homes.
  • For more information about Inmar, please follow us on Twitter, LinkedIn or Facebook , or call (866) 440-6917.